Vincent Capponi - Oct 4, 2024 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role: President and COO
Signature: /s/ Vincent Capponi
Stock symbol: CTSO
Transactions as of: Oct 4, 2024
Transactions value $: $0
Form type: 4
Date filed: 10/8/2024, 09:00 PM
Previous filing: Apr 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTSO	Stock Option (Right to Buy)	Award		+100K			100K	Oct 4, 2024	Common Stock	100K	$1.19	Direct	F1
transaction	CTSO	Stock Option (Right to Buy)	Award		+50K			50K	Oct 4, 2024	Common Stock	50K	$1.19	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.
F2	These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

Content

These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.